Evidence map›Paper›PMID 34242616›Full record

ArticleStem cell reports2021

Improved hematopoietic stem cell transplantation upon inhibition of natural killer cell-derived interferon-gamma.

Lorena Lobo de Figueiredo-Pontes, Miroslava K Adamcova, Srdjan Grusanovic, Maria Kuzmina, Izabela Aparecida Lopes, Amanda Fernandes de Oliveira Costa, Hong Zhang, Hynek Strnad, Sanghoon Lee, Alena Moudra and 5 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Stem Cell Therapy and Innate Lymphoid Cells.Stem cells international · 2022
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Lorena Lobo de Figueiredo-PontesHematology Division, Department of Medical Images, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14048-900, Brazil.
Miroslava K AdamcovaDepartment of Hemato-oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 142 00, Czech Republic; Childhood Leukaemia Investigation Prague, Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, University Hospital Motol, Prague 150 06, Czech Republic.
Srdjan GrusanovicDepartment of Hemato-oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 142 00, Czech Republic; Childhood Leukaemia Investigation Prague, Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, University Hospital Motol, Prague 150 06, Czech Republic; Faculty of Science, Charles University, Prague 128 00, Czech Republic.
Maria KuzminaDepartment of Hemato-oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 142 00, Czech Republic; Faculty of Science, Charles University, Prague 128 00, Czech Republic.
Izabela Aparecida LopesHematology Division, Department of Medical Images, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14048-900, Brazil.
Amanda Fernandes de Oliveira CostaHematology Division, Department of Medical Images, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14048-900, Brazil.
Hong ZhangHarvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.
Hynek StrnadDepartment of Genomics and Bioinformatics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 142 00, Czech Republic.
Sanghoon LeeDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Alena Moudra1(st) Department of Medicine - Department of Haematology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague 120 00, Czech Republic.
Anna T Jonasova1(st) Department of Medicine - Department of Haematology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague 120 00, Czech Republic.
Michal ZidkaOrthopaedic Department CLPA-Mediterra, Prague 190 00, Czech Republic; 3(rd) Medical Faculty, Charles University, Prague 100 00, Czech Republic.
Robert S WelnerHarvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Medicine, Division Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Daniel G TenenHarvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA; Cancer Science Institute, National University of Singapore, Singapore 117599, Singapore. Electronic address: daniel.tenen@nus.edu.sg.
Meritxell Alberich-JordaDepartment of Hemato-oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 142 00, Czech Republic; Childhood Leukaemia Investigation Prague, Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, University Hospital Motol, Prague 150 06, Czech Republic. Electronic address: alberich@img.cas.cz.
Czech Academy of Sciences, Institute of Molecular Genetics · CZCharles University · CZUniversidade de São Paulo · BRGeneral University Hospital in Prague · CZHarvard Stem Cell Institute · USHarvard University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Alabama at Birmingham · US

Funding

Transcriptional and epigenetic heterogeneity of stem/progenitor cellsP01HL131477 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI DANIEL G TENEN · 2017 to 2026
$24.6M
Mechanisms of regulation by RNA in acute myeloid leukemiaR35CA197697 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI TENEN, DANIEL G · 2015 to 2021
$7.1M
NCI NIH HHS R35 CA197697NHLBI NIH HHS P01 HL131477
6 · The paper itself

Abstract

Hematopoietic stem cell transplantation (HSCT) is a frequent therapeutic approach to restore hematopoiesis in patients with hematologic diseases. Patients receive a hematopoietic stem cell (HSC)-enriched donor cell infusion also containing immune cells, which may have a beneficial effect by eliminating residual neoplastic cells. However, the effect that donor innate immune cells may have on the donor HSCs has not been deeply explored. Here, we evaluate the influence of donor natural killer (NK) cells on HSC fate, concluded that NK cells negatively affect HSC frequency and function, and identified interferon-gamma (IFNγ) as a potential mediator. Interestingly, improved HSC fitness was achieved by NK cell depletion from murine and human donor infusions or by blocking IFNγ activity. Thus, our data suggest that suppression of inflammatory signals generated by donor innate immune cells can enhance engraftment and hematopoietic reconstitution during HSCT, which is particularly critical when limited HSC numbers are available and the risk of engraftment failure is high.

Indexed as

Tissue DonorsAnimalsCCAAT-Enhancer-Binding ProteinsCells, CulturedCoculture TechniquesGene Expression ProfilingGraft SurvivalHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansInterferon-gammaKiller Cells, NaturalLymphocyte DepletionMiceMice, Inbred C57BLMice, Inbred NODCCAAT-Enhancer-Binding ProteinsCebpg protein, mouseInterferon-gammaC/EBPgammahematopoietic stem cellhematopoietic stem cell transplantationinterferon-gammanatural killer cell

Identifiers

PMID34242616
PMCPMC8365098
OpenAlexW3182182803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.